FDA grants orphan drug designation to rencofilstat for hepatocellular carcinoma
The FDA granted orphan drug designation to rencofilstat for treatment of hepatocellular carcinoma, according to the agent’s manufacturer.Rencofilstat (Hepion Pharmaceuticals), a novel, potent cyclophilin inhibitor, is in clinical-phase development for treatment of nonalcoholic steatohepatitis (NASH), a major cause of HCC.The agent has been shown in experimental NASH models to lower liver fibrosis and HCC tumor burden, according to a Hepion Pharmaceuticals press release. It received FDA fast track designation last year for treatment of NASH.“Orphan drug designation for rencofilstatRead More
